TRADING IN NOVO NORDISK SHARES BY INSIDERS AND CONNECTED PERSONS AS REPORTED TO
NOVO NORDISK ON 24 AUGUST 2004
IN ACCORDANCE WITH SECTION 37 OF THE DANISH SECURITIES TRADING ACT, NOVO
NORDISK IS REQUIRED ON A DAILY BASIS TO PUBLISH INSIDERS' AND CONNECTED
PERSONS' TRADING IN THE NOVO NORDISK SHARE AS REPORTED BY INSIDERS TO NOVO
NORDISK, IN CASE NET TRADING FOR THE INSIDERS AND CONNECTED PERSONS AS A GROUP
EXCEEDS DKK 50,000.
Please find below a statement of the trading in the Novo Nordisk share by
insiders and connected persons as a group as reported to Novo Nordisk.
ID CODE DK001028081
TRADING PERIOD 24. AUGUST 2004
NET NUMBER OF SHARES TRADED 435
VALUE OF NET NUMBER OF SHARES TRADED IN DKK -966,005
TOTAL SHAREHOLDING, NUMBER OF SHARES 651,305
MARKET VALUE OF TOTAL SHAREHOLDING IN DKK 209,068,905
For definitions and background information please see below.
DEFINITIONS AND BACKGROUND INFORMATION:
WHO ARE INSIDERS AND CONNECTED PERSONS?
Insiders at Novo Nordisk are defined as members of the Board of Directors,
members of Executive Management, senior vice presidents and all employees
reporting directly to them, all employees in Corporate Legal, Corporate
Finance, Investor Relations and Corporate Communications, elected auditors and
their deputies as well as certain other employees who by the general counsel
have been categorised as insiders. Further, insiders include the following from
Novo Nordisk's parent organisation, Novo A/S and the Novo Nordisk Foundation:
members of the Board of Directors, members of Executive Management and other
employees who have access to inside information re Novo Nordisk, as well as
elected auditors. The insider register at Novo Nordisk comprises approximately
500 directors, executives and employees.
This group's reported trading in the Novo Nordisk share also includes trading
undertaken by insiders' spouses/cohabitants or children under the age of 18 as
well as any company, foundation and/or other businesses controlled by the
insider, his/her spouse/cohabitant and/or children under the age of 18
(connected persons). This brings the group to a total of approximately 1,500-
2,000 members. If the net value of the daily trading by this group does not
exceed DKK 50,000, Novo Nordisk is not obliged to issue a stock exchange
announcement on the trading undertaken by the group.
WHAT ARE ID CODE AND SHARES?
The ID code is the code (ISIN) of the Novo Nordisk share on the Copenhagen
Stock Exchange. Shares include shares listed on the Copenhagen Stock Exchange
and London Stock Exchange as well as ADRs listed on New York Stock Exchange,
except for ADRs held in 401(k) retirement plan by US-based employees.
WHAT IS TRADING PERIOD?
Trading period is the actual period in which the trading of the shares has
taken place.
WHAT ARE NET NUMBER OF SHARES TRADED AND VALUE OF NET NUMBER OF SHARES TRADED?
The net number of shares traded is the number of shares purchased or otherwise
acquired minus the number of shares sold or otherwise disposed of by the
insiders and connected persons as a group. The value of the net number of
shares traded is the difference between 1) the aggregate value of shares
acquired calculated at the actual trading prices for each trade and 2) the
aggregate value of shares disposed of calculated at the actual trading prices
for each trade. The Danish Central Bank's (Nationalbanken) exchange rate two
stock exchange days prior to the date of this announcement has been used for
calculating the actual trading price in DKK in case of shares traded on London
Stock Exchange and ADRs listed on New York Stock Exchange.
WHAT IS TOTAL SHAREHOLDING?
The total shareholding is the total number of shares held by the insiders and
connected persons as a group.
WHAT IS MARKET VALUE OF THE TOTAL SHAREHOLDING?
The market value is the total shareholding of the insiders and connected
persons as a group multiplied by the closing share price on the Copenhagen
Stock Exchange two stock exchange trading days prior to the date of this
announcement.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The
company has the broadest diabetes product portfolio in the industry, including
the most advanced products within the area of insulin delivery systems. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo
Nordisk manufactures and markets pharmaceutical products and services that make
a significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 18,800 full-time
employees in 69 countries, and markets its products in 179 countries. Novo
Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.
Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For
more information, visit novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Peter Haahr
Tel (direct): Tel (direct):
(+45) 4442 3450 (+45) 4442 1207
Palle Holm Olesen
Tel (direct):
(+45) 4442 6175
In North America: In North America:
Susan T Jackson Christian Kanstrup
Tel (direct): Tel (direct):
(+1) 609 919 7776 (+1) 609 919 7937
Stock Exchange Announcement No 51 / 2004